Lisata Therapeutics ( (LSTA) ) has issued an update.
Lisata Therapeutics reported promising third-quarter 2024 results, highlighting its expanding portfolio of innovative cancer therapies. The company’s novel drug, certepetide, is under multiple clinical trials for treating various solid tumors, including pancreatic cancer and glioblastoma. With a strong development pipeline and significant data readouts expected, Lisata is poised for a data-rich 2025, boosting investor interest. Financially, Lisata saw decreased operating expenses and maintained robust cash reserves, ensuring funding into 2026 while they anticipate further trial progress.
For detailed information about LSTA stock, go to TipRanks’ Stock Analysis page.
